AGT and kidney disorder: Urinary angiotensinogen has been proposed as a promising candidate and is now increasingly used as a marker of intrarenal RAS activation in studies of people with kidney diseases (Carrara et al., 2014; Cherney et al., 2014; Chou et al., 2018; Jung & Yoo, 2021; Kim et al., 2021; Kurultak et al., 2014; Matsuyama et al., 2018; Tiryaki et al., 2016; Tu & Pratt, 2013).